BCAX Heads Into Earnings With High Short Interest and an Activist on the Register
Bicara Therapeutics enters its November 10 earnings date carrying one of the heavier short burdens in clinical-stage biotech, an on-register activist, and a Street consensus that sits well above where the stock is…